Legionnela pneumophila pneumonia: Clinical and therapeutic aspects;Pneumonies à Legionnela pneumophila: Aspects cliniques et thérapeutiques

Medecine et Maladies Infectieuses

Volumn 33, Issue 11, 2003, Pages 549-553

  Chidiac, C ^a   Maulin, L ^a  

^a CROIX ROUSSE HOSPITAL   (France)

Author keywords

Anti infective chemotherapy; Community acquired pneumonia; Legionella pneumophila; Macrolide; Quinolone

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFALOTIN; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; DIRITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; JOSAMYCIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; PEFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; ROXITHROMYCIN; SPIRAMYCIN; TETRACYCLINE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; BACTERIAL PNEUMONIA; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE MODEL; DISEASE SEVERITY; DRUG INDICATION; EPIDEMIOLOGICAL DATA; GRAM STAINING; HUMAN; HYPONATREMIA; IN VITRO STUDY; LEGIONELLA PNEUMOPHILA; LEGIONNAIRE DISEASE; MULTIPLE ORGAN FAILURE; PNEUMONIA; RESPIRATORY SYSTEM; REVIEW; SECRETION; SYMPTOM; TREATMENT FAILURE;

EID: 0344443372     PISSN: 0399077X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-077X(03)00239-7     Document Type: Review

References (34)

1. e edition. In: Gorbach SL, Bartlett JG, Blacklow NR, editors. Infectious Diseases. Philadelphia: WB Sauders company Ed; 1997. p. 614-21.
2. Edelstein PH, Meyer RD. Legionella pneumonias. In: James E, Pennington, editors. Respiratory Infections: Diagnosis and management. New York: Raven Press Ed; 1994. p. 455-84.
3. Yu VL. Legionella pneumophila (Legionnaires' Disease). In: Principle and practice of Infectious Diseases (5e edition), Mandell GL, Bennet JE, Dolin Red, Churchill Livingstone Ed, New York, pp 2424-2435.
4. Cunha BA. Clinical features of Legionnaires' Disease. Seminars in respiratory infections 1998;13:116-27.
5. Léophonte P. Infections respiratoires bactériennes basses non tuberculeuses. In: Godard P, Bousquet J, Michel FB, editors. Maladies respiratoires. Paris: Masson Ed; 1993. p. 261-80.
6. APPIT. Pneumonies aiguës communautaires. Maladies infectieuses et tropicales. 2001. p. 154-65 2M2, montmorency.
7. Butler JC, Breiman RF. Legionellosis. In: Evans AS, Brachman PS, editors. Bacterial Infections of Humans, Epidemiology and Control. New York: Plenum Medical; 1998. p. 355-76.
8. Fraser DW, Tsai T, Orenstein W, et al. Legionnaires' disease: description of an epidemic of pneumonia. N Engl J Med 1977;297:1189-97.
9. Edelstein PH. Legionnaires' disease. Clin Infect Dis 1993;16:741-9.
10. Edelstein PH. Antimicrobial chemotherapy for legionnaires' disease: a review. Clin Infect Dis 1995 Dec;21(Suppl 3):S265-76.
11. Dedicoat M, Venkatesan P. The treatment of Legionnaires' disease. J Antimicrob Chemother 1999;43(6):747-52.
12. Fernandes PB, Bailer R, Swanson R, et al. In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. Antimicrob Agents Chemother 1986;30:865-73.
13. Kohno S, Koga H, Yamagushi K, et al. A new macrolide, TE-031 (A-56268), in treatment of experimental legionnaires'disease. J Antimicrob Chemother 1989;24:397-405.
14. Edelstein PH, Edelstein MAC. In vitro activity of azithromycin against clinical isolates of Legionella species. Antimicrob Agents Chemother 1991;35:180-1.
15. Edelstein PH. Review of azithromycin activity against Legionella species. Pathol Biol 1995;43:569-72.
16. Fitzgeorge RB, Featherstone ASR, Baskerville A. Efficacy of azithromycin in the treatment of guinea pigs infected with Legionella pneumophila by aerosol. J Antimicrob Chemother 1990;25(suppl A): 101-8.
17. Baltch AL, Smith RP, Ritz WJ, Francke MA, Michelsen PB. Antibacterial effect of telithromycin (HMR3647) and comparative antibiotics against intracellular Legionella pneumophila. J Antimicrob Chemother 2000;46:51-5.
18. Edelstein PH, Edelstein MAC. In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionellapneumophila pneumonia. Antimicrob Agents Chemother 1999;43:30-95.
19. Doumon E, Rajagapolan P, Pocidalo JJ, Vilde JL. Pefloxacin for treatment of experimental legionellosis 14th ICC, Kyoto. Abstr S85-11. 1985.
20. Saito A, Sawatari K, Fukuda Y, Nagasawa M, Koga H, Tomonaga A, et al. Susceptibility of Legionella pneumophila to ofloxacin in vitro and in experimental Legionella pneumonia in guinea pigs. Antimicrob Agents Chemother 1985;28:15-20.
21. Saito A, Koga H, Shigeno H, Watanabe K, Mori K, Kohno S, et al. The antimicrobial activity of ciprofloxacine against Legionella species and the treatment of experimental Legionella pneumonia in guinea pigs. J Antimicrob Chemother 1986;18:251-60.
22. Fitzgeorge R, Featherstone ASR, Baskerville A. Antibiotic therapy of experimental Legionnaires' disease; a comparison of the effect of ofloxacin, erythromycin and ciprofloxacine. 4th European congress of clinical microbiology, Nice Abstr 522PP23. 1989.
23. Chidiac C, Mouton Y. Quinolones in the treatment of lower respiratory tract infections caused by intracellular pathogens. Infection 1991;19(Suppl 7):S365-71.
24. Dubois J. Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp. JAC 2000;45(suppl. S1):41-6.
25. Baltch AL, et al. Antibacterial effect of levofloxacin, erythromycin and rifampicin a human monocyte system against Legionella pneumophila. AAC 1998;vol. 42(n° 12):3153-6.
26. Stout JE, et al. Comparative activity of ciprofloxacin, ofloxacin, levofloxacin and erythromycin against Legionella species by broth microdilution and intracellular susceptibility testing in H.L.-60 cells. Diag Microbiol Infect Dis 1998;30:37-43.
27. Edelstein PH, all BMS. 284756 (T - 3811ME a new fluoroquinolone: in vitro activity against Legionelle, efficacy in a guinea pig model of L. pneumophila pneumonia and pharmacokinetics in guinea pigs. J A antimicrob Chemother 2001;48:667-75.
28. Chidiac C, et al. Clinical aspect of Legionella pneumonia: a retrospective study assessing the efficacy and safety of levofloxacin monotherapy in 13 patients Edinburg UK. 10-12 june 2001.
29. Williams RR, et al. Levofloxacin is an effective therapy in the management of community acquired pneumonia (CAP) due to Legionella. Edinburgh: ISNQ; 10-12 june 2001. p. 113-7.
30. Jonas D, Engels I, Friedhoff C, Spitzmüller B, Daschner FD, Frank U. Efficacy of moxifloxacin, trovafloxacin, clinafloxacin and levofloxacin against intracellular Legionella pneumophila. J Antimicrob Chemother 2001;47:147-52.
31. Bartlett John G, Dowell Scott F, Mandell Lionel A, File Jr. Thomas M, Musher Daniel M, Fine Michael J. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000;31:347-82.
32. Mandell Lionel A, Marrie Thomas J, Grossman Ronald F, et al., the Canadian community-acquired pneumonia working group. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian infectious diseases society and the Canadian thoracic society. Clin Infect Dis 2000;31:383-421.
33. BTS CAP guidelines. Thorax 2001;56(suppl IV):IVI-IV64.
34. Afssaps:http://agmed.sante.gouv.fr/pdf/10/legion.pdf.